Edition:
United States

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

1.77USD
17 Aug 2018
Change (% chg)

$-0.22 (-11.06%)
Prev Close
$1.99
Open
$1.97
Day's High
$1.97
Day's Low
$1.77
Volume
7,721
Avg. Vol
12,521
52-wk High
$5.92
52-wk Low
$1.57

Latest Key Developments (Source: Significant Developments)

Sonoma Pharmaceuticals Closes $5 Million Public Offering
Tuesday, 6 Mar 2018 07:26pm EST 

March 6 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK.SONOMA PHARMACEUTICALS INC - ‍ANNOUNCED CLOSING OF PUBLIC OFFERING OF 1,428,570 SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $3.50 PER SHARE.  Full Article

Sonoma Pharmaceuticals Announces Pricing Of $5 Mln Public Offering Of Common Stock
Friday, 2 Mar 2018 08:00am EST 

March 2 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK.SONOMA PHARMACEUTICALS - PRICING OF "BEST EFFORTS" PUBLIC OFFERING OF UP TO 1.4 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.50/SHARE.  Full Article

Sonoma Pharma Revenue $4.8 Million For Third Quarter
Wednesday, 7 Feb 2018 04:05pm EST 

Feb 7 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%.Q3 REVENUE $4.8 MILLION.QTRLY LOSS EARNINGS PER SHARE FROM CONTINUING OPERATIONS $0.73.  Full Article

Sonoma Pharma Gets Three New UAE Regulatory Approvals
Tuesday, 9 Jan 2018 07:05am EST 

Jan 9 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS.SONOMA PHARMACEUTICALS INC - ANTICIPATE LAUNCHING ALL THREE PRODUCTS ACROSS UNITED ARAB EMIRATES IN FEBRUARY 2018.  Full Article

Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products
Tuesday, 5 Dec 2017 07:05am EST 

Dec 5 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS.  Full Article

Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn
Thursday, 16 Nov 2017 07:45am EST 

Nov 16 (Reuters) - Sonoma Pharmaceuticals Inc ::Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language.Approved Alevicyn dermal spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms​.  Full Article

Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million.Q2 revenue $4.3 million versus $2.8 million.Sonoma Pharmaceuticals qtrly loss per share from continuing operations​ $‍0.67.  Full Article

Sonoma Pharmaceuticals receives Brazilian approvals
Tuesday, 31 Oct 2017 07:45am EDT 

Oct 31 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products.Sonoma Pharmaceuticals Inc - ‍is currently seeking to partner with a Brazilian healthcare co relative to licensing newly approved products.Sonoma Pharmaceuticals Inc - ‍issuance of regulatory approvals by Brazilian Ministério Da Saúde for 7 of co's dermatology products​.  Full Article

Sonoma Pharmaceuticals Inc - qtrly‍ net loss per share basic and diluted, continuing operations $0.82​
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports financial results for first quarter of fiscal year 2018.Q1 revenue $3.8 million versus $2.6 million.Sonoma Pharmaceuticals Inc - qtrly ‍net loss per share basic and diluted, continuing operations $0.82​.  Full Article

Sonoma Pharmaceuticals reports qtrly loss per share from continuing operations $ 0.69
Monday, 5 Jun 2017 04:05pm EDT 

June 5 (Reuters) - Sonoma Pharmaceuticals Inc : :Sonoma Pharmaceuticals reports financial results for fourth quarter and fiscal year 2017.Q4 revenue $4.0 million versus $2.6 million.Qtrly loss per share from continuing operations $ 0.69.  Full Article

BRIEF-Sonoma Pharma Receives Four New Uae Regulatory Approvals That Include Acne And Anti-Fungal Products

* SONOMA PHARMACEUTICALS RECEIVES FOUR NEW UAE REGULATORY APPROVALS THAT INCLUDE ACNE AND ANTI-FUNGAL PRODUCTS